Chapter 4.1: Global Acne Market – 2013 -2023
4.1.1. Key Trends in the Global Acne Market
• Shift towards combination products: The acne market is currently
experiencing a gradual shift towards combination products that use two or more effective acne treatments. Currently marketed combination products, such as Duac (clindamycin phosphate and benzoyl peroxide) and Ziana (clindamycin phosphate and tretinoin), are expected to steadily increase revenue generation.
• Safety concerns on current drugs: There is a serious concern of safety and
efficacy in terms of the current drugs available. In June 2009 Accutane manufacturer Roche Pharmaceuticals recalled the drug from the US market as well as several other countries. In January 2013 French and Netherland health authorities moved to suspend sales of Bayer AG’s Diane 35 acne treatment, amid concerns the medicine increased the risk of blood clots.
Topical applications can turn the skin dry, irritated, red and can cause a burning sensation. Oral medications that include antibiotics and retinoids have led to increased hepatotoxicity, gastrointestinal issues and suicidal tendencies, along with the above mentioned issues.
• Efficacy concerns on current drugs: Drugs that are currently on the
market are unable to treat acne completely. Instead, they reduce the lesions by half but are unable to suppress re-occurrence of acne. The present drugs are also unable to target all the factors involved in acne pathology.
4.1.2 Market Size & Forecast
1. GMR Data estimates that the acne market across the seven major markets will
reach $3.3 bn by the end of 2013, covering approximately 50 million people globally.
2. The acne medication market is currently dominated by generic products.
Branded products now account for a relatively small portion of the overall market. However Differin generating $208m (FY ending May 2012) for Galderma and Solodyn generating $408m (FY ending May 2012) for Medicis are the clear leaders in the acne market.
3. Revenue growth slowdown has been attributed to the entry of generics coupled
with increased acceptance of alternative therapies such as photodynamic therapy and Ultraviolet (UV)/blue light therapy for acne treatment. Klox Technologies (Montreal, Canada) are one such advocate of light based technology treatments, trialling, in H2 2013, a non-invasive bio photonic (light-based) technology aimed at the acne market.
4. The Patent for Epiduo (benzoyl peroxide and adapalene) expired in late 2011,
Duac will expire in 2014; these factors will aid growth of the acne market during the forecast period.
5. Accutane (tretinoin) was withdrawn from the acne market due to severe
adverse events such as inflammatory bowel disease (IBD), ulcerative colitis and Crohn’s disease identified with prolonged usage of Accutane.
6. GMR Data estimate that the Acne market is forecasted to reach $4.7 bn in 2023
Table 4.1.2.a. Market Size & Forecast – Acne Market ($/bn, CAGR)
2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Page 1 sur 3 Questions Questions/Réponses Les contraceptifs oraux combinés (appelés le plus souvent « pilules »). 1. Qu’est-ce qu’un contraceptif oral combiné ? 2. Qu’est-ce qu’une thrombose veineuse ? 3. Qu’est ce qu’une thrombose artérielle ? 4. Quels sont les signes cliniques évocateurs de thrombose qui doivent amener à consulter en 5. Le risque de thromb
NEWSLETTER NOVEMBER/ DECEMBER 2009 During the past few months we have had several interesting events. There were the successful Exhibitions in The Gallery, of the work of Martin Snape and of Portsmouth Harbour as seen by Colin Baxter, also an interesting exhibition showing the work of the art teachers and their pupils from Hampshire schools. In keeping with the celebrations of Darwin's anniv